c-Met raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-12-10 and is reviewed periodically as new material appears.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Research codes vary by supplier |
| Appearance | White to off-white powder | Typical for lyophilized peptides |
| Solubility | Soluble in organic solvents; limited in water | Formulation dependent |
| Typical storage | −20 °C, desiccated, protected from light | Stability depends on purity and container |
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
{\displaystyle {\begin{aligned}&{\frac {dS}{dt}}=-a(t)SI-v(t)S,\\[6pt]&{\frac {dI}{dt}}=a(t)SI-\mu (t)I-\psi (t)I,\\[6pt]&{\frac {dR}{dt}}=\mu (t)I,\\[6pt]&{\frac {dV}{dt}}=v(t)S,\\[6pt]&{\frac {dD}{dt}}=\psi (t)I\end{aligned}}}
Prior to a law change in 2006, babies of non-citizens born in New Zealand were entitled to New Zealand citizenship. 18 February: Government Statistician Mark Sowden confirms he will resign on 30 March after an inquiry by the Public Service Commission into data breach allegations at Manurewa Marae in 2023 criticised Statistics New Zealand's handling of personal information and management of conflicts of interest. Torrential rain leads to flash flooding in parts of Otago including Beaumont. 19 February: The New Zealand Government establishes a NZ$2 million dual purpose fund to honour children who died in care and were buried in unmarked graves. A group of abuse survivors picket the Accident Compensation Corporation's Christchurch office, demanding the company reform eligibility coverage policies for abuse survivors. 20 February: Associate Immigration Minister Chris Penk uses his discretionary powers to grant Davan Kumar a residency visa but upholds the deportation order against his overstayer parents. Australian and New Zealand Defence Ministers Richard Marles and Judith Collins confirm that the Australian and New Zealand Defence Forces are monitoring three Chinese warships that are sailing through international waters near Sydney. New Zealand Media and Entertainment confirms plans to layoff several senior reporters and create a new Free ad-supported streaming television (FAST) channel. 21 February: Flights between Australia and New Zealand are diverted after the Chinese Navy conducts live fire drills using warships 340 nautical miles east of Sydney, in international waters.
== Arts and entertainment == Eighth octave C, a musical note, the highest on a piano Castle Infinity, the first graphical massively multiplayer online game C8 (French TV channel), a defunct French TV channel C8 (Eastern Europe), TV channel
== A == ABO blood group system – abscisic acid – absorption spectrum – abyssal zone – acetylcholine – acetyl-CoA – acid – acid precipitation – acoelomate – acrosome – actin – action potential – active site – adaptive radiation – address-message concept – adenosine 5'-triphosphate – adenylyl cyclase – adrenal gland – adrenodoxin – aerobic organism – age structure – agonist – AIDS – albumin – aldehydes – aldosterone – algae – allantois – allele – allometry – allopatric speciation – allosteric binding site – allosteric effector – allosteric enzyme – allosteric site – allozyme – alpha helix – amino acid – aminoacyl tRNA synthetase – amino group – amniocentesis – amniote – amphipathic molecule – anabolism – anaerobic organism – anaerobic respiration – androgen – anemia – aneuploidy – angiosperm – anther – anthrax – antibiotic – antibody – anticodon – antidiuretic hormone – antigen – apical dominance – apical meristem – apolipoprotein – apoplast – apoptosis – aquaporin – Archaea – archegonium – arteriosclerosis – artery – arthritis – ascus – asexual reproduction – atomic number – ATP – ATP synthase – atrioventricular valve – atrium – autoimmune disease – autonomic nervous system – autosome – auxin – axillary bud – axon
Sources: en.wikipedia.org
The structure of the native state is generally assumed to be determined by its amino acid sequence (Anfinsen's dogma). This is a thermodynamic principle which states that the native structure is a unique, stable and kinetically accessible minimum of the free energy. The thermodynamic path going from unfolded to the native state is typically visualized as a free energy landscape in the form of a folding funnel. The forces driving the folding is a combination of hydrophobic interacts, hydrogen bonding, van der Waals forces and Coloumb interactions. During folding, the number hydrophobic side-chains exposed to water is minimized, which is known as hydrophobic collapse, causing them to collapse into the core of the protein. This causes most globular proteins to have hydrophilic side-chains outwards on the surface exposed to solvent and hydrophobic side-chains in the core.
SELDI technology was developed by T. William Hutchens and Tai-Tung Yip at Baylor College of Medicine in 1993. Hutchens and Yip attached single-stranded DNA to agarose beads and used the beads to capture lactoferrin, an iron-binding glycoprotein, from preterm infant urine. The beads were incubated in the sample and then removed, washed, and analyzed with a MALDI-MS probe tip. This research led to the idea that MALDI surfaces could be derivatized with SEAC devices; the technique was later described by Hutchens and Yip in 1998. SELDI technology was first commercialized by Ciphergen Biosystems in 1997 as the ProteinChip system, and is now produced and marketed by Bio-Rad Laboratories.
== External links == The MEROPS online database for peptidases and their inhibitors: S01.217 Archived 2019-09-19 at the Wayback Machine Kujovich JL (February 2021). Adam MP, Ardinger HH, Pagon RA, et al. (eds.). "Prothrombin Thrombophilia". GeneReviews. Seattle WA: University of Washington, Seattle. PMID 20301327. NBK1148. Anti-coagulation & proteases on YouTube by The Proteolysis Map-animation [1] PMAP: The Proteolysis Map/Thrombin Thrombin: RCSB PDB Molecule of the Month Archived 2013-10-05 at the Wayback Machine Prothrombin Structure PDBe-KB provides an overview of all the structure information available in the PDB for Human Thrombin. PDBe-KB provides an overview of all the structure information available in the PDB for Mouse Thrombin.
Sources: en.wikipedia.org
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.
It is generally not regulated as a dietary supplement. Products are often sold as research chemicals. That status affects purity, labeling, and legal availability.
Dihexa itself is not a standard endogenous peptide. It is synthesized and modeled on angiotensin IV. Angiotensin IV occurs naturally as a fragment of angiotensin II.
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.